Europe Diabetes Care Devices Market: By Monitoring Devices (Self-monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices), By Management Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, Jet Injectors), By Delivery Types (Pumps, Pen, Syringes, Injectors, Cartridges in Reusable pens, Disposable Pens, Jet Injectors), By Distribution Channels (Institutional Sales, Hospitals, Clinics, Others, Retail Sales, Hospital pharmacies, Retail pharmacies, Online pharmacies), and Country

Europe Diabetes Care Devices Market size was valued at US$ 7,980.0 million in 2024 and is expected to reach US$ 10,787.2 million by 2031, growing at a significant CAGR of 4.4% from 2025-2031. Diabetes care devices are used to monitor diabetics' blood glucose levels. Diabetes care devices are medical devices that track and monitor diabetes patients' blood glucose levels throughout the day. This wearable device will benefit diabetics by assisting them in managing their glucose levels. Moreover, the rise in obesity as well as rising awareness about diabetes management in Europe are the driving factors that drive the growth of the Europe diabetes care devices market. According to the International Diabetes Federation, 21,600 children are added to the type 1 diabetic population pool each year. According to these figures, diabetes accounts for approximately 9% of total healthcare expenditure in Europe. Various government initiatives, such as the National Service Framework (NSF) programme in the United Kingdom, are improving services by establishing national standards to drive up service quality and address variations in care.

However, the glucose testing device is costly and can be painful. Furthermore, the results of diabetes care devices are not always accurate. Factors such as painful sensor insertions and the difficulty of fitting multiple devices on small bodies along with the disruptive alerts lost signals, resulting in data gaps, skin irritation, and adhesive issues impede market expansion. Several government initiatives and awareness campaigns are also driving market growth. The UK DESMOND education programme is a structured patient education and management programme for newly diagnosed type 2 diabetes patients. Its goal is to help people identify early health risks. There has also been an increase in government funding for healthcare.

According to the International Diabetes Federation, diabetes-related healthcare spending is rapidly increasing. Moreover, reimbursement and pricing policies are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some market opportunities. Further, technological advancements have increased over the period in Diabetes care devices for safer and more accurate administration of insulin. Medtronic launched its first integrated smart insulin pen. The Medtronic Integrated Insulin Pen provides real-time glucose readings of patients along with insulin dose information to manage their glucose levels.

Key Developments

• In 2021, Medtronic received a CE mark for its InPen smart insulin pen and Guardian 4 sensor for better diabetes management.
• In 2021, Medtronic launched the Medtronic Extended infusion set in selected European countries, making it the first and only one that can be worn for up to 7 days.